E
Pasithea Therapeutics Corp. KTTA
$1.19 -$0.02-1.65%
Recommendation
Sell
Prev Close
$1.21
Volume
45,465
Avg Vol (90D)
762,923
Market Cap
$1.53M
Dividend & Yield
--
52-Week Range
$0.9226 - $9.25
P/E (TTM)
--
EPS (TTM)
-$14.83
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E+
Very Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Very Weak
Dividend Index
--
Headlines
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update
2/27/2025 - Ticker Report
ARMISTICE CAPITAL, LLC Acquires Shares in Pasithea Therapeutics Corp
2/15/2025 - GuruFocus
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ...
2/5/2025 - GuruFocus
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
2/5/2025 - Globe Newswire
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial ...
1/14/2025 - GuruFocus
Pasithea Therapeutics opens three clinical trial sites in Eastern Europe
1/14/2025 - The Fly
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
1/14/2025 - Globe Newswire
Analyzing Pasithea Therapeutics (NASDAQ:KTTA) and#038; MusclePharm (OTCMKTS:MSLP)
12/16/2024 - Ticker Report
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ...
11/20/2024 - GuruFocus
Pasithea Therapeutics announces SRC recommended proceeding to cohort 4
11/20/2024 - The Fly
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
11/20/2024 - Globe Newswire
ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeutics Corp
11/15/2024 - GuruFocus
Short Interest in Pasithea Therapeutics Corp. (NASDAQ:KTTA) Grows By 42,725.0%
10/10/2024 - Ticker Report
Pasithea Therapeutics files to sell 3.74M shares of common stock for holders
10/7/2024 - SeekingAlpha.com: All News
Pasithea Therapeutics files to sell 3.74M shares of common stock for holders
10/7/2024 - The Fly
Critical Analysis: Pasithea Therapeutics (NASDAQ:KTTA) and Novo Nordisk A/S (NYSE:NVO)
10/4/2024 - Zolmax
Analyzing Pasithea Therapeutics (NASDAQ:KTTA) & Novo Nordisk A/S (NYSE:NVO)
10/4/2024 - Ticker Report
Pasithea Therapeutics drops 19% on $5M private placement
9/27/2024 - SeekingAlpha.com: All News
Pasithea Therapeutics drops 19% on $5M private placement
9/27/2024 - Seeking Alpha - Healthcare
Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share
9/26/2024 - The Fly
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
9/26/2024 - Globe Newswire
Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004
9/26/2024 - The Fly
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
9/26/2024 - Globe Newswire
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update
9/26/2024 - Ticker Report
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$15.49M
EBIT (TTM)
-$16.14M
Net Income (TTM)
-$15.78M
Balance Sheet
Total Assets (Q)
$18.64M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$824.00K
Book Value Per Share (Q)
$17.05
Cash Flow
Cash from Operations (TTM)
-$15.39M
Cash from Investing (TTM)
$648.90K
Cash from Financing (TTM)
$4.54M
Net Change in Cash (TTM)
-$10.22M
Filings
Filing Date
Wednesday, November 13, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
0.87
7-Day Total Return
-7.75%
30-Day Total Return
-52.21%
60-Day Total Return
-58.10%
90-Day Total Return
-70.54%
Year to Date Total Return
-59.39%
1-Year Total Return
-83.47%
2-Year Total Return
-87.89%
3-Year Total Return
-94.73%
5-Year Total Return
--
52-week Low
Mar 04, 2025 - $0.9226
52-week High
Apr 08, 2024 - $9.25
Valuation
Market Cap
$1.53M - Nano Cap
Enterprise Value
-$7.83M
Price/Sales (TTM)
--
Price/Book (Q)
0.07
Dividends and Shares
Shares Outstanding
1.04M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.pasithea.com
Phone Number
702 514 4174
Address
1111 Lincoln Road
Miami Beach, FL 33139
Country
United States
Year Founded
2020
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead... more
NASDAQ 03/07/2025 4:00PM Eastern Quotes delayed
Weiss Ratings